Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV001508379 | SCV001714500 | uncertain significance | not provided | 2019-10-10 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003145680 | SCV003829403 | uncertain significance | Anemia, congenital dyserythropoietic, type 1a | 2021-10-09 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003298912 | SCV004002173 | uncertain significance | Inborn genetic diseases | 2023-05-23 | criteria provided, single submitter | clinical testing | The c.187C>T (p.R63C) alteration is located in exon 2 (coding exon 2) of the CDAN1 gene. This alteration results from a C to T substitution at nucleotide position 187, causing the arginine (R) at amino acid position 63 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |